City

Clinical trials near Changsha, China

Active studies with a listed research site in Changsha, China.

16active studies

11recruiting now

9countries represented

201largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Dementia, Mild, Mild Cognitive ImpairmentCondition

Mazdutide, PlaceboTreatment

China8 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-09-02 · NCT07083154See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 1

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

Overweight or ObesityCondition

KN069Treatment

China1 locations

Suzhou Alphamab Co., Ltd.Sponsor

Updated 2025-09-17 · NCT06547775See eligibility →

Recruiting nowNot applicable

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

ObesityCondition

Attapulgite, PlaceboTreatment

China1 locations

Second Xiangya Hospital of Central South UniversitySponsor

Updated 2025-09-05 · NCT07103382See eligibility →

Recruiting nowNot applicable

Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe Obesity

Obesity, Bariatric SurgeryCondition

Intervention not listedTreatment

China1 locations

The Third Xiangya Hospital of Central South UniversitySponsor

Updated 2025-07-30 · NCT07093502See eligibility →

Recruiting nowPhase 2

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

Overweight or ObeseCondition

THDBH120 injection, Placebo of THDBH120 injectionTreatment

China1 locations

Tonghua Dongbao Pharmaceutical Co.,LtdSponsor

Updated 2025-06-25 · NCT07036601See eligibility →

Opening soonPhase 2

AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents

Obesity, Obese AdolescentsCondition

AKK, Placebo (maltodextrin)Treatment

China1 locations

Central South UniversitySponsor

Updated 2026-06-03 · NCT07593170See eligibility →

Opening soonPhase 3

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

Overweight or ObesityCondition

MDR-001, PlaceboTreatment

China45 locations

MindRank AI LtdSponsor

Updated 2025-12-22 · NCT07274137See eligibility →

Opening soonNot applicable

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

Severe ObesityCondition

Sleeve gastrectomy plus early mazdutide initiation, Sleeve gastrectomy followed with early mazdutide placebo initationTreatment

China14 locations

Beijing Friendship HospitalSponsor

Updated 2025-08-21 · NCT07135141See eligibility →

Opening soonPhase 3

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

ObesityCondition

TQF3510 (Semaglutide Injection), Wegovy®Treatment

China66 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2024-12-18 · NCT06738979See eligibility →

Active, not recruitingNot applicable

Changes in Fat and Muscle Tissue Function and Their Impact on Metabolic Health After Bariatric Surgery

Obesity and Obesity-related Medical Conditions, Sarcopenic ObesityCondition

bariatric surgeryTreatment

China1 locations

Shaihong ZhuSponsor

Updated 2025-06-25 · NCT07035483See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Changsha, China

Current studies

Related cities